Oral contraceptives use and risk of cervical cancer-A systematic review & meta-analysis

被引:52
作者
Asthana, Smita [1 ]
Busa, Vishal [1 ]
Labani, Satyanarayana [1 ]
机构
[1] Indian Council Med Res, Div Epidemiol & Biostat, Natl Inst Canc Prevent & Res, Noida, UP, India
关键词
Cervical cancer; Meta-analysis; OC pills; Risk; Systematic review; HUMAN-PAPILLOMAVIRUS INFECTION; HORMONAL CONTRACEPTIVES; INTRAEPITHELIAL NEOPLASIA; SMOKING; WOMEN; HPV; ASSOCIATION; CARCINOMA; ADENOCARCINOMAS; PREGNANCY;
D O I
10.1016/j.ejogrb.2020.02.014
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background: Role of Oral Contraceptive (OC) as a risk factor for cervical cancer remained controversial and unclear. Objective: To evaluate risk of cervical cancer in OC users and non-users through a comprehensive systematic review. Search strategy: Literature search conducted in databases from January 1990 till August 2019 using various search terms. Selection criteria: Primary research studies that evaluated and assessed the association of OC use with cervical cancer with study design of case control or cohort types published in English language. Data collection and analysis: PRISMA guided review was done by two independent researchers. Effect size estimated by pooled Odds ratio with 95 % Confidence Interval (CI) in random effect models on OC pill use for the risk of cervical cancer. Results: Review included 19 studies. Overall risk of invasive cancer on OC use was found to be significant with unknown status of HPV OR (95 % CI) as 1.51 (1.35, 1.68) and for unknown HPV as 1.66 (1.24, 2.21). Adenocarcinoma, squamous cell carcinoma and carcinoma in situ had significant association with OR (95 % CI) of 1.77 (1.4, 2.24), 1.29 (1.18, 1.42) and 1.7 (1.18, 2.44) respectively. Conclusion: OC pills use had a definite associated risk for developing cervical cancer specially for Adenocarcinoma and longer duration of OC pills use. (c) 2020 Elsevier B.V. All rights reserved.
引用
收藏
页码:163 / 175
页数:13
相关论文
共 49 条
[1]  
[Anonymous], ORAL CONTRACEPTIVES
[2]  
[Anonymous], HORM MOL BIOL CLIN I
[3]  
Appleby P, 2007, LANCET, V370, P1609, DOI 10.1016/S0140-6736(07)61684-5
[4]  
BERRY G, 1993, INT J CANCER, V55, P228
[5]  
Bond Sharon, 2014, J Midwifery Womens Health, DOI [10.1111/jmwh.12202, 10.1111/jmwh.12179_3]
[6]   ORAL-CONTRACEPTIVE USE AND RISK OF INVASIVE CERVICAL-CANCER [J].
BRINTON, LA ;
REEVES, WC ;
BRENES, MM ;
HERRERO, R ;
DEBRITTON, RC ;
GAITAN, E ;
TENORIO, F ;
GARCIA, M ;
RAWLS, WE .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1990, 19 (01) :4-11
[7]   Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology [J].
Castle, PE ;
Walker, JL ;
Schiffman, M ;
Wheeler, CM .
INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (06) :1007-1012
[8]  
Castle PE, 2002, JNCI-J NATL CANCER I, V94, P1406, DOI 10.1093/jnci/94.18.1406
[9]   Hormonal and barrier methods of contraception, oncogenic human papillomaviruses, and cervical squamous intraepithelial lesion development [J].
Coker, AL ;
Sanders, LC ;
Bond, SM ;
Gerasimova, T ;
Pirisi, L .
JOURNAL OF WOMENS HEALTH & GENDER-BASED MEDICINE, 2001, 10 (05) :441-449
[10]  
Darney PD, 1997, INT J FERTIL WOMEN M, V42, P158